Astex shapes CDK4/6 inhibitor for approval

Kisqali (ribociclib), a frontline treatment for metastatic breast cancer developed by Basel, Switzerland–based Novartis, won approval from the US Food and Drug Administration (FDA)…

Click here  to original publication.

Fonte: 396 VOLUME 35 NUMBER 5 MAY 2017 NATURE BIOTECHNOLOGY